{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T07:20:51Z","timestamp":1763018451646,"version":"3.37.3"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,8]],"date-time":"2021-10-08T00:00:00Z","timestamp":1633651200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,10,8]],"date-time":"2021-10-08T00:00:00Z","timestamp":1633651200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1038\/s41409-021-01485-6","type":"journal-article","created":{"date-parts":[[2021,10,8]],"date-time":"2021-10-08T12:26:36Z","timestamp":1633695996000},"page":"43-50","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Outcomes of third allogeneic hematopoietic stem cell transplantation in relapsed\/refractory acute leukemia after a second transplantation"],"prefix":"10.1038","volume":"57","author":[{"given":"Shinichi","family":"Kobayashi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4866-9307","authenticated-orcid":false,"given":"Yoshinobu","family":"Kanda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1496-376X","authenticated-orcid":false,"given":"Takaaki","family":"Konuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4881-0427","authenticated-orcid":false,"given":"Yoshihiro","family":"Inamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimikazu","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5952-5926","authenticated-orcid":false,"given":"Naoyuki","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5421-7470","authenticated-orcid":false,"given":"Kazuhiro","family":"Ikegame","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihiro","family":"Miyamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriko","family":"Doki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirohisa","family":"Nakamae","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5054-9104","authenticated-orcid":false,"given":"Yuta","family":"Katayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5528-7112","authenticated-orcid":false,"given":"Souichi","family":"Shiratori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoji","family":"Saito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiro","family":"Kawakita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6704-3633","authenticated-orcid":false,"given":"Junya","family":"Kanda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4404-2870","authenticated-orcid":false,"given":"Yoshiko","family":"Atsuta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6223-9904","authenticated-orcid":false,"given":"Fumihiko","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,10,8]]},"reference":[{"key":"1485_CR1","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/s41409-019-0584-3","volume":"55","author":"NM Moukalled","year":"2020","unstructured":"Moukalled NM, Kharfan-Dabaja MA. What is the role of a second allogeneic hematopoietic cell transplant in relapsed acute myeloid leukemia? Bone Marrow Transpl. 2020;55:325\u201331. https:\/\/doi.org\/10.1038\/s41409-019-0584-3. e-pub ahead of print 2019\/06\/05","journal-title":"Bone Marrow Transpl"},{"key":"1485_CR2","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1038\/s41409-020-01163-z","volume":"56","author":"M Yanada","year":"2021","unstructured":"Yanada M, Konuma T, Yamasaki S, Kondo T, Fukuda T, Shingai N, et al. Relapse of acute myeloid leukemia after allogeneic hematopoietic cell transplantation: clinical features and outcomes. Bone Marrow Transpl. 2021;56:1126\u201333. https:\/\/doi.org\/10.1038\/s41409-020-01163-z. e-pub ahead of print 2020\/12\/04","journal-title":"Bone Marrow Transpl"},{"key":"1485_CR3","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1038\/bmt.2015.186","volume":"50","author":"T Ruutu","year":"2015","unstructured":"Ruutu T, de Wreede LC, van Biezen A, Brand R, Mohty M, Dreger P, et al. Second allogeneic transplantation for relapse of malignant disease: retrospective analysis of outcome and predictive factors by the EBMT. Bone Marrow Transpl. 2015;50:1542\u201350. https:\/\/doi.org\/10.1038\/bmt.2015.186. e-pub ahead of print 2015\/09\/15","journal-title":"Bone Marrow Transpl"},{"key":"1485_CR4","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/bmt.2015.221","volume":"51","author":"R Vrhovac","year":"2016","unstructured":"Vrhovac R, Labopin M, Ciceri F, Finke J, Holler E, Tischer J, et al. Second reduced intensity conditioning allogeneic transplant as a rescue strategy for acute leukaemia patients who relapse after an initial RIC allogeneic transplantation: analysis of risk factors and treatment outcomes. Bone Marrow Transpl. 2016;51:186\u201393. https:\/\/doi.org\/10.1038\/bmt.2015.221. e-pub ahead of print 2015\/10\/06","journal-title":"Bone Marrow Transpl"},{"key":"1485_CR5","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1038\/sj.bmt.1704645","volume":"34","author":"M Eapen","year":"2004","unstructured":"Eapen M, Giralt SA, Horowitz MM, Klein JP, Wagner JE, Zhang MJ, et al. Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant. Bone Marrow Transpl. 2004;34:721\u20137. https:\/\/doi.org\/10.1038\/sj.bmt.1704645. e-pub ahead of print 2004\/08\/24","journal-title":"Bone Marrow Transpl"},{"key":"1485_CR6","doi-asserted-by":"publisher","first-page":"3259","DOI":"10.1200\/JCO.2012.44.7961","volume":"31","author":"M Christopeit","year":"2013","unstructured":"Christopeit M, Kuss O, Finke J, Bacher U, Beelen DW, Bornhauser M, et al. Second allograft for hematologic relapse of acute leukemia after first allogeneic stem-cell transplantation from related and unrelated donors: the role of donor change. J Clin Oncol. 2013;31:3259\u201371. https:\/\/doi.org\/10.1200\/JCO.2012.44.7961","journal-title":"J Clin Oncol"},{"key":"1485_CR7","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1001\/jamaoncol.2018.2091","volume":"4","author":"MA Kharfan-Dabaja","year":"2018","unstructured":"Kharfan-Dabaja MA, Labopin M, Polge E, Nishihori T, Bazarbachi A, Finke J, et al. Association of second allogeneic hematopoietic cell transplant vs donor lymphocyte infusion with overall survival in patients with acute myeloid leukemia relapse. JAMA Oncol. 2018;4:1245\u201353. https:\/\/doi.org\/10.1001\/jamaoncol.2018.2091. e-pub ahead of print 2018\/07\/14","journal-title":"JAMA Oncol"},{"key":"1485_CR8","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1038\/bmt.2015.193","volume":"50","author":"G Andreola","year":"2015","unstructured":"Andreola G, Labopin M, Beelen D, Chevallier P, Tabrizi R, Bosi A, et al. Long-term outcome and prognostic factors of second allogeneic hematopoietic stem cell transplant for acute leukemia in patients with a median follow-up of 10 years. Bone Marrow Transpl. 2015;50:1508\u201312. https:\/\/doi.org\/10.1038\/bmt.2015.193. e-pub ahead of print 2015\/09\/22","journal-title":"Bone Marrow Transpl"},{"key":"1485_CR9","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.beha.2016.10.011","volume":"29","author":"D Weisdorf","year":"2016","unstructured":"Weisdorf D. The role of second transplants for leukemia. Best Pr Res Clin Haematol. 2016;29:359\u201364. https:\/\/doi.org\/10.1016\/j.beha.2016.10.011. e-pub ahead of print 2016\/11\/29","journal-title":"Best Pr Res Clin Haematol"},{"key":"1485_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-019-0251-3","volume":"9","author":"A Shimoni","year":"2019","unstructured":"Shimoni A, Labopin M, Finke J, Ciceri F, Deconinck E, Kroger N, et al. Donor selection for a second allogeneic stem cell transplantation in AML patients relapsing after a first transplant: a study of the Acute Leukemia Working Party of EBMT. Blood Cancer J. 2019;9:88 https:\/\/doi.org\/10.1038\/s41408-019-0251-3. e-pub ahead of print 2019\/11\/20","journal-title":"Blood Cancer J"},{"key":"1485_CR11","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1046\/j.1365-2141.2000.01851.x","volume":"108","author":"M Michallet","year":"2000","unstructured":"Michallet M, Tanguy ML, Socie G, Thiebaut A, Belhabri A, Milpied N, et al. Second allogeneic haematopoietic stem cell transplantation in relapsed acute and chronic leukaemias for patients who underwent a first allogeneic bone marrow transplantation: a survey of the Societe Francaise de Greffe de moelle (SFGM). Br J Haematol. 2000;108:400\u20137. https:\/\/doi.org\/10.1046\/j.1365-2141.2000.01851.x. e-pub ahead of print 2000\/02\/26","journal-title":"Br J Haematol"},{"key":"1485_CR12","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1111\/bjh.15973","volume":"186","author":"A Nagler","year":"2019","unstructured":"Nagler A, Labopin M, Dholaria B, Finke J, Brecht A, Schanz U, et al. Second allogeneic stem cell transplantation in patients with acute lymphoblastic leukaemia: a study on behalf of the Acute Leukaemia Working Party of the European Society for Blood and Marrow Transplantation. Br J Haematol. 2019;186:767\u201376. https:\/\/doi.org\/10.1111\/bjh.15973. e-pub ahead of print 2019\/05\/23","journal-title":"Br J Haematol"},{"key":"1485_CR13","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1038\/s41409-021-01267-0","volume":"56","author":"A Sharma","year":"2021","unstructured":"Sharma A, Li Y, Huang S, Talleur AC, Suliman A, Qudeimat A, et al. Outcomes of pediatric patients who relapse after first HCT for acute leukemia or MDS. Bone Marrow Transpl. 2021;56:1866\u201375. https:\/\/doi.org\/10.1038\/s41409-021-01267-0. e-pub ahead of print 2021\/03\/21","journal-title":"Bone Marrow Transpl"},{"key":"1485_CR14","doi-asserted-by":"publisher","unstructured":"Kharfan-Dabaja MA, Labopin M, Bazarbachi A, Ciceri F, Finke J, Bruno B et al. Comparing outcomes of a second allogeneic hematopoietic cell transplant using HLA-matched unrelated versus T-cell replete haploidentical donors in relapsed acute lymphoblastic leukemia: a study of the Acute Leukemia Working Party of EBMT. Bone Marrow Transplant 2021. e-pub ahead of print 2021\/05\/02; https:\/\/doi.org\/10.1038\/s41409-021-01317-7","DOI":"10.1038\/s41409-021-01317-7"},{"key":"1485_CR15","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.bbmt.2014.10.006","volume":"21","author":"CN Duncan","year":"2015","unstructured":"Duncan CN, Majhail NS, Brazauskas R, Wang Z, Cahn JY, Frangoul HA, et al. Long-term survival and late effects among one-year survivors of second allogeneic hematopoietic cell transplantation for relapsed acute leukemia and myelodysplastic syndromes. Biol Blood Marrow Transpl. 2015;21:151\u20138. https:\/\/doi.org\/10.1016\/j.bbmt.2014.10.006. e-pub ahead of print 2014\/10\/16","journal-title":"Biol Blood Marrow Transpl"},{"key":"1485_CR16","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1182\/blood-2011-08-375840","volume":"119","author":"C Schmid","year":"2012","unstructured":"Schmid C, Labopin M, Nagler A, Niederwieser D, Castagna L, Tabrizi R, et al. Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation. Blood. 2012;119:1599\u2013606. https:\/\/doi.org\/10.1182\/blood-2011-08-375840. e-pub ahead of print 2011\/12\/15","journal-title":"Blood"},{"key":"1485_CR17","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1016\/j.bbmt.2018.03.002","volume":"24","author":"I Yaniv","year":"2018","unstructured":"Yaniv I, Krauss AC, Beohou E, Dalissier A, Corbacioglu S, Zecca M, et al. Second hematopoietic stem cell transplantation for post-transplantation relapsed acute leukemia in children: a retrospective EBMT-PDWP study. Biol Blood Marrow Transpl. 2018;24:1629\u201342. https:\/\/doi.org\/10.1016\/j.bbmt.2018.03.002. e-pub ahead of print 2018\/03\/20","journal-title":"Biol Blood Marrow Transpl"},{"key":"1485_CR18","doi-asserted-by":"publisher","first-page":"2491","DOI":"10.1007\/s00277-018-3454-y","volume":"97","author":"C Schneidawind","year":"2018","unstructured":"Schneidawind C, Hagmaier V, Faul C, Kanz L, Bethge W, Schneidawind D. Second allogeneic hematopoietic cell transplantation enables long-term disease-free survival in relapsed acute leukemia. Ann Hematol. 2018;97:2491\u20132500. https:\/\/doi.org\/10.1007\/s00277-018-3454-y. e-pub ahead of print 2018\/08\/02","journal-title":"Ann Hematol"},{"key":"1485_CR19","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.bbmt.2018.09.016","volume":"25","author":"TC Lund","year":"2019","unstructured":"Lund TC, Ahn KW, Tecca HR, Hilgers MV, Abdel-Azim H, Abraham A, et al. Outcomes after second hematopoietic cell transplantation in children and young adults with relapsed acute leukemia. Biol Blood Marrow Transpl. 2019;25:301\u20136. https:\/\/doi.org\/10.1016\/j.bbmt.2018.09.016. e-pub ahead of print 2018\/09\/24","journal-title":"Biol Blood Marrow Transpl"},{"key":"1485_CR20","first-page":"825","volume":"15","author":"D Przepiorka","year":"1995","unstructured":"Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transpl. 1995;15:825\u20138. e-pub ahead of print 1995\/06\/01","journal-title":"Bone Marrow Transpl"},{"key":"1485_CR21","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.bbmt.2008.12.497","volume":"15","author":"S Giralt","year":"2009","unstructured":"Giralt S, Ballen K, Rizzo D, Bacigalupo A, Horowitz M, Pasquini M, et al. Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transpl. 2009;15:367\u20139. https:\/\/doi.org\/10.1016\/j.bbmt.2008.12.497. e-pub ahead of print 2009\/02\/11","journal-title":"Biol Blood Marrow Transpl"},{"key":"1485_CR22","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transpl. 2013;48:452\u20138. https:\/\/doi.org\/10.1038\/bmt.2012.244. e-pub ahead of print 2012\/12\/05","journal-title":"Bone Marrow Transpl"},{"key":"1485_CR23","doi-asserted-by":"publisher","first-page":"408 e401","DOI":"10.1016\/j.jtct.2021.01.025","volume":"27","author":"A Rank","year":"2021","unstructured":"Rank A, Peczynski C, Labopin M, Stelljes M, Simand C, Helbig G, et al. Feasibility and outcomes of a third allogeneic hematopoietic stem cell transplantation: a retrospective analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Transpl Cell Ther. 2021;27:408 e401\u2013408 e406. https:\/\/doi.org\/10.1016\/j.jtct.2021.01.025. e-pub ahead of print 2021\/05\/10","journal-title":"Transpl Cell Ther"},{"key":"1485_CR24","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1007\/s12185-015-1755-7","volume":"101","author":"T Konuma","year":"2015","unstructured":"Konuma T, Kato S, Ooi J, Ebihara Y, Mochizuki S, Oiwa-Monna M, et al. Third allogeneic stem cell transplantation (SCT) using unrelated cord blood for relapsed acute leukemia after second allogeneic SCT. Int J Hematol. 2015;101:392\u20137. https:\/\/doi.org\/10.1007\/s12185-015-1755-7. e-pub ahead of print 2015\/02\/07","journal-title":"Int J Hematol"},{"key":"1485_CR25","doi-asserted-by":"publisher","first-page":"5675","DOI":"10.1200\/JCO.2005.07.061","volume":"23","author":"C Schmid","year":"2005","unstructured":"Schmid C, Schleuning M, Ledderose G, Tischer J, Kolb HJ. Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol. 2005;23:5675\u201387. https:\/\/doi.org\/10.1200\/JCO.2005.07.061. e-pub ahead of print 2005\/08\/20","journal-title":"J Clin Oncol"},{"key":"1485_CR26","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1111\/bjh.14428","volume":"176","author":"O Ringden","year":"2017","unstructured":"Ringden O, Labopin M, Schmid C, Sadeghi B, Polge E, Tischer J, et al. Sequential chemotherapy followed by reduced-intensity conditioning and allogeneic haematopoietic stem cell transplantation in adult patients with relapse or refractory acute myeloid leukaemia: a survey from the Acute Leukaemia Working Party of EBMT. Br J Haematol. 2017;176:431\u20139. https:\/\/doi.org\/10.1111\/bjh.14428. e-pub ahead of print 2016\/11\/24","journal-title":"Br J Haematol"},{"key":"1485_CR27","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/s41409-019-0624-z","volume":"55","author":"J Styczynski","year":"2020","unstructured":"Styczynski J, Tridello G, Koster L, Iacobelli S, van Biezen A, van der Werf S, et al. Death after hematopoietic stem cell transplantation: changes over calendar year time, infections and associated factors. Bone Marrow Transpl. 2020;55:126\u201336. https:\/\/doi.org\/10.1038\/s41409-019-0624-z. e-pub ahead of print 2019\/08\/29","journal-title":"Bone Marrow Transpl"},{"key":"1485_CR28","doi-asserted-by":"publisher","first-page":"6283","DOI":"10.1182\/bloodadvances.2020003418","volume":"4","author":"O Penack","year":"2020","unstructured":"Penack O, Peczynski C, Mohty M, Yakoub-Agha I, Styczynski J, Montoto S, et al. How much has allogeneic stem cell transplant-related mortality improved since the 1980s? A retrospective analysis from the EBMT. Blood Adv. 2020;4:6283\u201390. https:\/\/doi.org\/10.1182\/bloodadvances.2020003418. e-pub ahead of print 2020\/12\/23","journal-title":"Blood Adv"},{"key":"1485_CR29","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1111\/bjh.15898","volume":"186","author":"Y Shimomura","year":"2019","unstructured":"Shimomura Y, Hara M, Tachibana T, Ohashi K, Sakura T, Fukuda T, et al. Outcomes of second allogeneic haematopoietic stem cell transplantation in patients with relapse of myelodysplastic syndrome. Br J Haematol. 2019;186:86\u201390. https:\/\/doi.org\/10.1111\/bjh.15898. e-pub ahead of print 2019\/04\/04","journal-title":"Br J Haematol"},{"key":"1485_CR30","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.3324\/haematol.2018.204438","volume":"104","author":"Y Maeda","year":"2019","unstructured":"Maeda Y, Ugai T, Kondo E, Ikegame K, Murata M, Uchida N, et al. HLA discrepancy between graft and host rather than that graft and first donor impact the second transplant outcome. Haematologica. 2019;104:1055\u201361. https:\/\/doi.org\/10.3324\/haematol.2018.204438. e-pub ahead of print 2018\/12\/14","journal-title":"Haematologica"},{"key":"1485_CR31","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/bmt.2008.300","volume":"43","author":"R Guilfoyle","year":"2009","unstructured":"Guilfoyle R, Demers A, Bredeson C, Richardson E, Rubinger M, Szwajcer D, et al. Performance status, but not the hematopoietic cell transplantation comorbidity index (HCT-CI), predicts mortality at a Canadian transplant center. Bone Marrow Transpl. 2009;43:133\u20139. https:\/\/doi.org\/10.1038\/bmt.2008.300. e-pub ahead of print 2008\/09\/03","journal-title":"Bone Marrow Transpl"},{"key":"1485_CR32","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.bbmt.2004.10.008","volume":"11","author":"R Wong","year":"2005","unstructured":"Wong R, Shahjahan M, Wang X, Thall PF, De Lima M, Khouri I, et al. Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation. Biol Blood Marrow Transpl. 2005;11:108\u201314. https:\/\/doi.org\/10.1016\/j.bbmt.2004.10.008. e-pub ahead of print 2005\/02\/01","journal-title":"Biol Blood Marrow Transpl"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-021-01485-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-021-01485-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-021-01485-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,5]],"date-time":"2022-01-05T12:04:42Z","timestamp":1641384282000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-021-01485-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,8]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["1485"],"URL":"https:\/\/doi.org\/10.1038\/s41409-021-01485-6","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"type":"print","value":"0268-3369"},{"type":"electronic","value":"1476-5365"}],"subject":[],"published":{"date-parts":[[2021,10,8]]},"assertion":[{"value":"5 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}